Successful establishment of Abingdon Health USA Inc facilities since launch in April 2025
Since April 2025, when its Madison facilities began operations, the Company has worked with many customers and potential customers wanting US-based CDMO services for lateral flow tests. Project details are confidential, but the wide-ranging areas currently in progress via contract development projects with US customers include:
- Development of a duplex lateral flow to quantitatively measure the concentrations of a pharmaceutical product and its metabolite.
- Development of a lateral flow veterinary product for use initially in canine samples.
- Feasibility work with a leading US university to evaluate novel nanoparticles for use in a lateral flow format.
- Development of a lateral flow test for infectious disease initially in bovine animals.
- Development of a test for an infectious agent in animals and humans, with a spin-out of leading US university.
- All of these projects are being run from the Madison facility with support from colleagues at the Company's UK facilities.
These contract wins underline the importance of Abingdon Health's expansion of its CDMO offering in the US, extending its global reach to current and new US-based clients. Abingdon Health's value proposition, which provides customers with comprehensive support to take an "idea through to commercial success", is resonating well in the USA.
Expansion of US facility
Abingdon Health also announces that the second phase of its US facility expansion in Madison is underway with plans commenced for the installation of high-throughput manufacturing to enable the seamless transition of projects from development into manufacturing. The manufacturing equipment will mirror Abingdon Health's UK operation to allow customers to manufacture under the same operating conditions and quality management system in either the USA, the UK, or both. This provides customers with unrivalled geographic optionality during a period of tariff and supply chain uncertainty and provides US customers with the confidence that products "developed in the USA" by the Company's highly skilled CDMO team can also be "made in the USA".
Dr Chris Hand, Executive Chairman of Abingdon Health plc, commented:
"These contract awards validate our decision to expand our CDMO operations into the USA and we anticipate further expansion in Madison, Wisconsin, as projects and products move through the development cycle. It is pleasing to see our US customers recognise the value of our comprehensive CDMO platform. We deliver end-to-end diagnostic solutions from initial concept through to market launch, and these contract wins illustrate strong confidence in our approach from US-based clients".
